On November 12, 2021, the Company entered into a certain Open Market Sale Agreement (the “Sale Agreement”) with Jefferies LLC (“Jefferies”) relating to shares of our common stock, $0.0001 par value per share, offered pursuant to an effective shelf registration statement on Form S-3 that was declared effective on May 6, 2021. In accordance with the terms of the Sale Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $30,000 from time to time through Jefferies acting as our agent. Note 17. Stock-Based Compensation The following table reflects the components of stock-based compensation expense recognized in the Company's Consolidated Statements of Operations: Year Ended December 31, 2021 2020 Phantom units: Cost of revenue — 27 Selling, general and administrative — (23) Research and development — 36 Total phantom units stock-based compensation expense — 40 Stock options: Cost of revenue 188 100 Selling, general and administrative 3,012 1,688 Research and development 424 246 Total stock options stock-based compensation expense 3,624 2,034 Restricted stock units: Cost of revenue — 9 Selling, general and administrative 128 621 Research and development — 23 Total restricted stock units stock-based compensation expense 128 653 Related party share based payments Selling, general and administrative 67 — Research and development 68 — Total related party stock-based compensation expense 135 — Discontinued operations — (79) Total stock-based compensation expense 3,887 2,648 Amount capitalized to internal-use software 118 97 Total stock-based compensation cost $ 4,005 $ 2,745 NantHealth, Inc. Notes to Consolidated Financial Statements (Dollars in thousands, except per share amounts) - 130 -
RkJQdWJsaXNoZXIy NTIzOTM0